{"id":"NCT03009396","sponsor":"RedHill Biopharma Limited","briefTitle":"Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease","officialTitle":"An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-18","primaryCompletion":"2018-11-13","completion":"2019-08-19","firstPosted":"2017-01-04","resultsPosted":"2021-02-24","lastUpdate":"2021-02-24"},"enrollment":54,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn Disease"],"interventions":[{"type":"DRUG","name":"RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)","otherNames":["RHB-104"]}],"arms":[{"label":"RHB-104 - patients on ACTIVE therapy in RHB-104-01 study","type":"EXPERIMENTAL"},{"label":"RHB-104 - patients on PLACEBO therapy in RHB-104-01 study","type":"EXPERIMENTAL"}],"summary":"An open label extension to the RHB-104-01 Study.","primaryOutcome":{"measure":"Number of Patients in Remission at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"RHB-104 From ACTIVE Arm of RHB-104-01","deltaMin":3,"sd":null},{"arm":"RHB-104 From PLACEBO Arm of RHB-104-01","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States","Canada","Czechia","Israel","New Zealand","Poland","Serbia"]},"refs":{"pmids":[],"seeAlso":["http://www.redhillbio.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":16},"commonTop":["Chromaturia","Crohn's Disease","Nausea","Abdominal pain","Arthralgia"]}}